AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

CSPC received an upfront payment of $100 million from AstraZeneca and is also eligible to receive up to $1.92 billion for further development and commercialization milestones, plus tiered royalties.

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in ...

CSPC said the compound was discovered by the Group's AI-driven small molecule drug design platform. AstraZeneca's London-listed shares slipped 0.2% on Monday but have gained 11% this year.

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's rules on approving new medicines as well as a row over drug prices.